Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07527832

An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan.

Sponsor: Pfizer

View on ClinicalTrials.gov

Summary

The purpose of this study is to look at the safety of BEVACIZUMAB BS \[Pfizer\] when it was used to colorectal cancer patients in real-world clinical setting in Japan. The study population includes individuals who have a diagnosis of colorectal cancer and have been treated with Bevacizumab-Pfizer Biosimilar or Avastin between 1 December 2019 and 30 November 2024. Data source is the Medical Data Vision (MDV) database - a hospital-based claims database in Japan.

Official title: BEVACIZUMAB BS INTRAVENOUS INFUSION 100MG, 400MG [PFIZER] POST-MARKETING DATABASE STUDY

Key Details

Gender

All

Age Range

15 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1000

Start Date

2026-04-20

Completion Date

2026-05-31

Last Updated

2026-05-28

Healthy Volunteers

No

Interventions

DRUG

Bevacizumab-Pfizer Biosimilar

As provided in real world practice

DRUG

Avastin

As provided in real world practice

Locations (1)

Pfizer

Tokyo, Japan